X4 PHARMACEUTICALS is a biopharmaceutical company. Co.'s primary clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4, that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, mavorixafor has the potential to provide therapeutic benefit across a variety of neutropenic disorders, including Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, primary immunodeficiency. Co. is also developing mavorixafor in a Phase 2 clinical trial in people with certain neutropenic disorders. The XFOR average annual return since 2017 is shown above.
The Average Annual Return on the XFOR average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XFOR average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XFOR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|